Syndax Pharmaceuticals Inc’s recently made public that its Chief Financial Officer Goldan Keith A. acquired Company’s shares for reported $25037.0 on Jun 14 ’24. In the deal valued at $20.03 per share,1,250 shares were bought. As a result of this transaction, Goldan Keith A. now holds 52,623 shares worth roughly $1.15 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
UBS initiated its Syndax Pharmaceuticals Inc [SNDX] rating to a Buy in a research note published on October 24, 2024; the price target was $37. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late June with a ‘”a Buy”‘ rating. Scotiabank also remained covering SNDX and has decreased its forecast on January 31, 2024 with a “Sector perform” recommendation from previously “Sector outperform” rating. Mizuho started covering the stock on December 22, 2023. It rated SNDX as “a Buy”.
Price Performance Review of SNDX
On Monday, Syndax Pharmaceuticals Inc [NASDAQ:SNDX] saw its stock fall -0.14% to $21.78. Over the last five days, the stock has gained 14.99%. Syndax Pharmaceuticals Inc shares have risen nearly 0.79% since the year began. Nevertheless, the stocks have risen 61.57% over the past one year. While a 52-week high of $25.34 was reached on 02/28/24, a 52-week low of $13.14 was recorded on 09/18/24. SMA at 50 days reached $19.14, while 200 days put it at $20.99.
Levels Of Support And Resistance For SNDX Stock
The 24-hour chart illustrates a support level at 21.39, which if violated will result in even more drops to 20.99. On the upside, there is a resistance level at 22.34. A further resistance level may holdings at 22.89. The Relative Strength Index (RSI) on the 14-day chart is 71.69, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.96, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 18.05%. Stochastics %K at 83.41% indicates the stock is a selling.
How much short interest is there in Syndax Pharmaceuticals Inc?
A steep rise in short interest was recorded in Syndax Pharmaceuticals Inc stocks on 2024-10-15, growing by 0.84 million shares to a total of 10.51 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-13 was 9.67 million shares. There was a rise of 7.99%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 25, 2023 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
